Skip to main content
PMC home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1999 May;89(5):731–736. doi: 10.2105/ajph.89.5.731

Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

P Jacob 3rd 1, L Yu 1, A T Shulgin 1, N L Benowitz 1
PMCID: PMC1508721  PMID: 10224986

Abstract

OBJECTIVES: This study (1) determined levels of various tobacco alkaloids in commercial tobacco products. (2) determined urinary concentrations, urinary excretion, and half-lives of the alkaloids in humans; and (3) examined the possibility that urine concentrations of nicotine-related alkaloids can be used as biomarkers of tobacco use. METHODS: Nicotine intake from various tobacco products was determined through pharmacokinetic techniques. Correlations of nicotine intake with urinary excretion and concentrations of anabasine, anatabine, nornicotine, nicotine, and cotinine were examined. By using urinary excretion data, elimination half-lives of the alkaloids were calculated. RESULTS: Alkaloid levels in commercial tobacco products, in milligrams per gram, were as follows: nicotine, 6.5 to 17.5; nornicotine, 0.14 to 0.66; anabasine, 0.008 to 0.030; and anatabine, 0.065 to 0.27. Measurable concentrations of all alkaloids were excreted in the urine of most subjects smoking cigarettes, cigars, and pipes and using smokeless tobacco. Correlations between nicotine intake and alkaloid concentrations were good to excellent. CONCLUSIONS: Anabasine and anatabine, which are present in tobacco but not in nicotine medications, can be used to assess tobacco use in persons undergoing nicotine replacement therapy.

Full text

PDF
732

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen R. A., Burton H. R., Fleming P. D., Hamilton-Kemp T. R. Effect of storage conditions on nitrosated, acylated, and oxidized pyridine alkaloid derivatives in smokeless tobacco products. Cancer Res. 1989 Nov 1;49(21):5895–5900. [PubMed] [Google Scholar]
  2. Armitage A., Dollery C., Houseman T., Kohner E., Lewis P. J., Turner D. Absorption of nicotine from small cigars. Clin Pharmacol Ther. 1978 Feb;23(2):143–151. doi: 10.1002/cpt1978232143. [DOI] [PubMed] [Google Scholar]
  3. Beckett A. H., Gorrod J. W., Jenner P. A possible relation between pKa 1 and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man. J Pharm Pharmacol. 1972 Feb;24(2):115–120. doi: 10.1111/j.2042-7158.1972.tb08943.x. [DOI] [PubMed] [Google Scholar]
  4. Benowitz N. L. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev. 1996;18(2):188–204. doi: 10.1093/oxfordjournals.epirev.a017925. [DOI] [PubMed] [Google Scholar]
  5. Benowitz N. L., Hall S. M., Herning R. I., Jacob P., 3rd, Jones R. T., Osman A. L. Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med. 1983 Jul 21;309(3):139–142. doi: 10.1056/NEJM198307213090303. [DOI] [PubMed] [Google Scholar]
  6. Benowitz N. L., Jacob P., 3rd Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther. 1984 Apr;35(4):499–504. doi: 10.1038/clpt.1984.67. [DOI] [PubMed] [Google Scholar]
  7. Benowitz N. L., Jacob P., 3rd, Denaro C., Jenkins R. Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther. 1991 Mar;49(3):270–277. doi: 10.1038/clpt.1991.28. [DOI] [PubMed] [Google Scholar]
  8. Benowitz N. L., Jacob P., 3rd, Kozlowski L. T., Yu L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med. 1986 Nov 20;315(21):1310–1313. doi: 10.1056/NEJM198611203152102. [DOI] [PubMed] [Google Scholar]
  9. Benowitz N. L., Jacob P., 3rd Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther. 1994 Nov;56(5):483–493. doi: 10.1038/clpt.1994.169. [DOI] [PubMed] [Google Scholar]
  10. Benowitz N. L., Jacob P., 3rd, Yu L. Daily use of smokeless tobacco: systemic effects. Ann Intern Med. 1989 Jul 15;111(2):112–116. doi: 10.7326/0003-4819-111-2-112. [DOI] [PubMed] [Google Scholar]
  11. Benowitz N. L. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597–613. doi: 10.1146/annurev.pa.36.040196.003121. [DOI] [PubMed] [Google Scholar]
  12. Benowitz N. L. Smoking-induced coronary vasoconstriction: implications for therapeutic use of nicotine. J Am Coll Cardiol. 1993 Sep;22(3):648–649. doi: 10.1016/0735-1097(93)90171-v. [DOI] [PubMed] [Google Scholar]
  13. Clark M. S., Rand M. J., Vanov S. Comparison of pharmacological activity of nicotine and related alkaloids occurring in cigarette smoke. Arch Int Pharmacodyn Ther. 1965 Aug;156(2):363–379. [PubMed] [Google Scholar]
  14. Galeazzi R. L., Daenens P., Gugger M. Steady-state concentration of cotinine as a measure of nicotine-intake by smokers. Eur J Clin Pharmacol. 1985;28(3):301–304. doi: 10.1007/BF00543327. [DOI] [PubMed] [Google Scholar]
  15. Hoffmann D., Hecht S. S. Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res. 1985 Mar;45(3):935–944. [PubMed] [Google Scholar]
  16. Jacob P., 3rd, Yu L., Liang G., Shulgin A. T., Benowitz N. L. Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. J Chromatogr. 1993 Sep 8;619(1):49–61. doi: 10.1016/0378-4347(93)80445-a. [DOI] [PubMed] [Google Scholar]
  17. Jacob P., 3rd, Yu L., Wilson M., Benowitz N. L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom. 1991 May;20(5):247–252. doi: 10.1002/bms.1200200503. [DOI] [PubMed] [Google Scholar]
  18. Nguyen T. L., Gruenke L. D., Castagnoli N., Jr Metabolic oxidation of nicotine to chemically reactive intermediates. J Med Chem. 1979 Mar;22(3):259–263. doi: 10.1021/jm00189a008. [DOI] [PubMed] [Google Scholar]
  19. Sepkovic D. W., Haley N. J. Biomedical applications of cotinine quantitation in smoking related research. Am J Public Health. 1985 Jun;75(6):663–665. doi: 10.2105/ajph.75.6.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shigenaga M. K., Kim B. H., Caldera-Munoz P., Cairns T., Jacob P., 3rd, Trevor A. J., Castagnoli N., Jr Liver and lung microsomal metabolism of the tobacco alkaloid beta-nicotyrine. Chem Res Toxicol. 1989 Sep-Oct;2(5):282–287. doi: 10.1021/tx00011a003. [DOI] [PubMed] [Google Scholar]
  21. Turner J. A., Sillett R. W., McNicol M. W. Effect of cigar smoking on carboxyhaemoglobin and plasma nicotine concentrations in primary pipe and cigar smokers and ex-cigarette smokers. Br Med J. 1977 Nov 26;2(6099):1387–1389. doi: 10.1136/bmj.2.6099.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES